Antithrombin agents as anticoagulants and antithrombotics: implications in drug development

Area of Science:

• Pharmacology
• Biochemistry
• Hematology

Background:

• Direct thrombin inhibitors have evolved over 40 years from synthetic benzamidines to peptide derivatives and recombinant hirudin.
• Understanding thrombin's structure and function has driven the development of targeted anticoagulant therapies.
• Heparin-induced thrombocytopenia (HIT) has increased the demand for alternative anticoagulants like direct thrombin inhibitors.

Purpose of the Study:

• To review the historical development and current status of direct thrombin inhibitors.
• To highlight the mechanisms of action and diverse applications of these anticoagulants.
• To discuss ongoing research and unresolved issues in the field, including oral agent development.

Main Methods:

• Review of historical scientific literature and drug development pathways.
• Analysis of biochemical mechanisms of thrombin inhibition.
• Examination of clinical applications and pharmacological differences of various inhibitors.

Main Results:

• Direct thrombin inhibitors target thrombin, providing anticoagulation and inhibiting coagulation cascade amplification.
• Several intravenous and subcutaneous direct thrombin inhibitors are in development for various indications.
• Synthetic inhibitors may also affect other coagulation enzymes, leading to complex effects.

Conclusions:

• Direct thrombin inhibitors represent a significant advancement in anticoagulation therapy.
• Ongoing research focuses on developing oral agents and resolving issues like monitoring and long-term safety.
• Careful clinical evaluation is necessary due to the complex effects and distinct pharmacologic profiles of these agents.